Rocatinlimab shows real-world promise for moderate to severe AD, enhancing treatment efficacy and reducing steroid reliance, explains Emma Guttman-Yassky, MD, PhD.
Changing the FDA biosimilar interchangeability standards is a necessary but likely insufficient step to improve biosimilar competition in the US.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback